drugset
drugset / Trial / NCT03774459

ANAVEX2-73 Study in Parkinson's Disease Dementia

NCT03774459 ↗

Phase 2 Completed 132 enrolled Anavex Life Sciences Corp. Anavex Germany GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Timeline

Start
2018-07-09
Primary completion
2020-09-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Blarcamesine Small molecule — Oral

Indications

Parkinson disease